Truist Financial Forecasts Strong Price Appreciation for Lantheus (NASDAQ:LNTH) Stock

Lantheus (NASDAQ:LNTH) had its price target raised by analysts at Truist Financial from $120.00 to $127.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price target suggests a potential upside of 35.12% from the company’s current price.

LNTH has been the subject of a number of other research reports. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $132.86.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $93.99 on Thursday. The stock’s 50-day simple moving average is $89.81 and its 200-day simple moving average is $96.78. The firm has a market capitalization of $6.53 billion, a PE ratio of 15.71 and a beta of 0.44. Lantheus has a fifty-two week low of $56.44 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, sell-side analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Several institutional investors and hedge funds have recently made changes to their positions in LNTH. Janus Henderson Group PLC raised its position in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC raised its position in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after buying an additional 435,445 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Lantheus in the 4th quarter valued at approximately $36,183,000. Finally, Groupama Asset Managment purchased a new position in Lantheus during the third quarter worth $439,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.